Literature DB >> 14524732

Improving health-related quality of life in gastro-oesophageal reflux disease.

Michael J Shaw1, Joseph A Crawley.   

Abstract

Gastro-oesophageal reflux disease (GORD) is a common, chronic disorder that can progress to erosive or ulcerative oesophagitis and other complications. Uncomplicated GORD can be defined using criteria that combine symptom assessment and the impact of symptoms on well being or quality of life. The extent of impairment of health-related quality of life (HRQL) in GORD patients has been evaluated using generic HRQL questionnaires, GORD-specific quality of life questionnaires or a combination of the two types of instruments. The impact of GORD on HRQL in affected individuals is proportional to the frequency and severity of heartburn, and is greater than that associated with many other chronic diseases. In the treatment of GORD, the goal should be complete symptom resolution as this has been shown to be associated with a clinically significant improvement in HRQL. Both drug treatment and surgical intervention have been successful in improving HRQL of patients with GORD when complete symptom resolution can be attained.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14524732     DOI: 10.2165/00003495-200363210-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  45 in total

Review 1.  Treatment of gastroesophageal reflux disease: use of algorithms to aid in management.

Authors:  P O Katz
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

2.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

3.  Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease.

Authors:  D A Revicki; S Sorensen; P N Maton; R C Orlando
Journal:  Dig Dis       Date:  1998 Sep-Oct       Impact factor: 2.404

Review 4.  Nonerosive reflux disease--current concepts and dilemmas.

Authors:  R Fass; M B Fennerty; N Vakil
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

Review 5.  Safety issues relating to long-term treatment with histamine H2-receptor antagonists.

Authors:  S M Sabesin
Journal:  Aliment Pharmacol Ther       Date:  1993       Impact factor: 8.171

6.  Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.

Authors:  Kerstin Röhss; Göran Hasselgren; Hans Hedenström
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

7.  The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.

Authors:  R Fass; J J Ofman; R E Sampliner; L Camargo; C Wendel; M B Fennerty
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

8.  Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases.

Authors:  E Dimenäs
Journal:  Scand J Gastroenterol Suppl       Date:  1993

9.  The effect of treating reflux oesophagitis with omeprazole on quality of life.

Authors:  N I McDougall; J S Collins; R J McFarland; R G Watson; A H Love
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-06       Impact factor: 2.566

10.  Detecting anxiety and depression in general medical settings.

Authors:  D Goldberg; K Bridges; P Duncan-Jones; D Grayson
Journal:  BMJ       Date:  1988-10-08
View more
  5 in total

Review 1.  Patient-reported outcomes (PRO's) in glaucoma: a systematic review.

Authors:  S Vandenbroeck; S De Geest; T Zeyen; I Stalmans; F Dobbels
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

Review 2.  Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures.

Authors:  Nicholas J Talley; Ingela Wiklund
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

3.  A Study on the Correlation Between Endoscopic Findings and Symptoms of Gastroesophageal Reflux Disease (GERD).

Authors:  Rajesh Domakunti; Yeshwant R Lamture
Journal:  Cureus       Date:  2022-04-21

Review 4.  The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

5.  Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.

Authors:  Thomas O Kovacs; James W Freston; Marian M Haber; Stuart Atkinson; Barbara Hunt; David A Peura
Journal:  Dig Dis Sci       Date:  2009-07-07       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.